Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ Launching 3 Exhilarating 7-night Itineraries From Barcelona With Overnights in Ibiza
Virgin Voyages, the new lifestyle brand shaking up the travel industry, announced their second ship will be called ‘Valiant Lady’ and that she will sail 7-night Mediterranean itineraries out of Barcelona, Spain when she debuts in May 2021. Bookings for the three feature itineraries, that all offer overnight and late-night stops across some of the hottest destinations in France, Italy and Spain, will open December 19, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005362/en/
Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ (Graphic: Business Wire)
“We are thrilled to unveil the name of our second ship - Valiant Lady - and to deliver on our commitment to offer travelers a sea change in how they can experience cruising in this fantastic part of the world. Our Sailors will fall in love with the places we go and the moments and memories they will be able to create on our gorgeous ship. After all, there is no better way to sail the seven seas than doing it the Virgin way,” said Tom McAlpin, CEO of Virgin Voyages.
2021 Summers on the Med with a home in Barcelona
Valiant Lady will dock just steps from Las Ramblas at the World Trade Center Barcelona, positioning Sailors as close to the heart of this stunning departure-port-city as possible. This prime location, usually reserved by luxury liners and mega-yachts, gives walking access to the dynamic and diverse neighborhoods of Poble Sec, el Raval, Barri Gotic, Port Vell and the famed urban beach of La Barceloneta. With a weekly Sunday sail away, Sailors will enjoy extra time in Barcelona and be able to take advantage of many different flight options. Virgin Voyages is partnering with Global Ports Holding, the world’s leading independent cruise port operator, to prepare for Valiant Lady’s arrival in early summer 2021.
Open for bookings December 2019, 7 night sailings start May 2021 and feature an overnight in Ibiza
The Med, home to some of the world’s best beach clubs, cultural experiences, restorative spas, yacht clubs and nightlife, is a perfect choice for Virgin Voyages. Valiant Lady will sail 3 different itineraries with truly breathtaking ports of call.
- Itinerary 1 includes the exotic delights of Barcelona, Ibiza, Monte Carlo, Marseille and Olbia
- Itinerary 2 includes a fantastic sampling of the Med featuring Barcelona, Ibiza, Toulon, Ajaccio, Marina di Carrara and Cagliari
- Itinerary 3 is a mostly Spanish immersion, stopping by Barcelona, Ibiza, Palma de Mallorca, Malaga and the British port of Gibraltar
Hearing Sailor and First Mates (travel partners) requests for later stays in ports, Virgin has delivered this on every itinerary. This means Sailors have the flexibility to make the most of their time in port and take in all that these destinations have to offer. Of particular note, every sailing features a Friday overnight stay in Ibiza, one of the most stunning and thrilling Balearic Islands. Whether it’s a blissed out beach club, a bohemian market, a serene spa, watching the stunning sunsets, or a late night out, there is no comparable place that offers the variety and style of this ultimate destination.
Introducing ‘Valiant Lady’
Virgin Voyages also revealed that the name ‘Valiant Lady’ was inspired by the Latin word valere and from the French origin, vaillant, meaning “bold”, “strong”, and “courageous." While historically, the image of women only graced the bows of ships to bring protection to a vessel, ‘Valiant Lady’ embodies the idea that women design, captain, lead and champion change in the maritime industry.
The Scarlet Lady’s sister ship ‘Valiant Lady’ will continue Virgin Voyages’ ‘Scarlet Squad’ program aimed at recruiting, supporting and mentoring female shipboard talent, and growing opportunities to access leadership roles in onboard areas such as marine, technical and hotel management that statistically show low numbers of female leadership.
All Virgin Voyages ships have been designed by a leading creative collective who are the brains behind some of the world’s most loved boutique hotel brands. The collective includes names like Design Research Studio (Tom Dixon), Roman & Williams and Concrete Amsterdam who have all been inspired by the brand’s design concept- the Modern Romance of Sailing and Mission to Redefine the Experience of a Vacation at Sea.
Future Sailors, First Mates and travel advisors are invited to check out Virgin Voyages by visiting www.virginvoyages.com or following @virginvoyages on Instagram, Facebook, Twitter or LinkedIn.
ABOUT VIRGIN VOYAGES
Virgin Voyages is a global lifestyle brand committed to creating the world’s most irresistible holidays. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and Europe. Virgin Voyages’ ships are designed to reflect a super yacht’s sleek luxury, featuring spaces designed by some of the top names in contemporary interiors. An Adult-by-Design sanctuary, the ships offer a dose of Vitamin Sea with well-being activated through a mix of high-energy moments coupled with relaxation and rejuvenation. Scarlet Lady will also feature never before seen entertainment and 20+ world-class intimate eateries on board. Virgin Voyages offers incredible value for its sailors with all restaurants, group fitness classes, soft drinks, and many more Virgin surprises included within the voyage fare. Scarlet Lady will sail from Miami to the Caribbean all year round from March 2020 and Valiant Lady will sail the Mediterranean from May 2021. The fleet's ships host more than 2,770 sailors and 1,160 amazing crew from around the world. Keep watch on virginvoyages.com for more updates.
FOLLOW VIRGIN VOYAGES:
Instagram: @virginvoyages
Facebook: @virginvoyages
Twitter: @virginvoyages
LinkedIn: Virgin Voyages
YouTube: Virgin Voyages
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005362/en/
Contact information
ALISON BROD MARKETING + COMMUNICATIONS
Virgin@alisonbrodmc.com
Virgin Voyages
Michelle Estevam, media@virginvoyages.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom